收缩储备对左心室功能障碍患者接受TAVI治疗的临床结果的影响
Yeela Talmor-Barkan1, Amos Levi1, Marco Barbanti2
1The Department of Cardiology, Rabin Medical Center, Petach-Tikva, Israel; The Gray Faculty of Medicine & Health Science, Tel-Aviv University, Tel-Aviv, Israel.
International journal of cardiology
|September 21, 2025
概括
多布他胺应激心声学 (DSE) 在接受过导管大动脉植入 (TAVI) 的患者中识别了收缩储备 (CR). 阳性CR预测了更好的射出小部分恢复和减少3年死亡率在严重的大动脉狭窄与左心室功能障碍.
科学领域:
- 心脏病学 心脏病学
- 心声回声扫描 (Echocardiography) 是一种心声回声扫描.
- 干预心脏病学 干预心脏病学
背景情况:
- 患有严重的大动脉狭窄 (AS) 和左心室 (LV) 功能障碍的患者在透气管大动脉植入 (TAVI) 后表现不佳.
- 关于多布胺应激心声学 (DSE) 在TAVI中对这一高危人群的患者选择的有用性,数据有限.
研究的目的:
- 评估由 DSE.发现的收缩储备 (CR) 的预后值.
- 评估TAVI后CR和射出分数 (EF) 恢复之间的关联.
主要方法:
- 一个多中心注册包括296名患者EF≤30%接受TAVI.
- 患者根据收缩储备的存在 (CR+) 或缺乏 (CR-) 进行了分类.
- 主要终点是3年死亡率,并对TAVI后EF恢复进行了二次分析.
主要成果:
- 与CR- (43.7%) 相比,CR+ (34.0%) 的患者的3年死亡率明显较低.
- 收缩储备 (CR+) 是EF恢复的独立预测因素 (OR 6.06).
- EF恢复与较低的3年死亡率 (29.6%与45.1%) 有关.
结论:
- DSE的收缩储备 (CR) 与死亡率的降低有关,主要是通过改善EF恢复.
- DSE和CR评估可以帮助对TAVI进行严重AS和LV功能障碍患者的分组.
- 支持在选定的患者中进行DSE的常规使用,用于TAVI前评估.
相关概念视频
01:27Regulation of Stroke Volume
4.7K
The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
4.7K
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
461
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
461
01:29Heart Failure II: Pathophysiology
734
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
734
01:26Heart Failure III: Clinical Manifestations
511
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
511
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
01:22Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261